Skip to main content

The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Anti-Tumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models.

Publication ,  Journal Article
Ma, J; Hegde, S; Sergeeva, M; Chakraborty, B; Wardell, SE; McDonnell, DP; Huang, PQ; Bunker, KD; Doñate, F; Lackner, MR; Samatar, AA
Published in: Mol Cancer Ther
December 12, 2025

Endocrine therapy has proven to be beneficial for patients with estrogen receptor (ER) positive, HER2 negative (ER+/HER2-) breast cancer; however, de novo or acquired resistance remains a major clinical challenge. Upon progression, many of the cancers continue to be ER dependent, highlighting the opportunities for novel ER targeting therapies. Fulvestrant, a selective estrogen receptor degrader (SERD) that antagonizes and degrades ER simultaneously, has demonstrated activity in ER+/HER2- breast cancers the ability to overcome endocrine resistance. Fulvestrant has limitations including challenging administration by intramuscular injection and poor bioavailability, resulting in sub-optimal drug exposure, hence several next generation oral SERDs with improved drug properties have been developed and are currently being evaluated in the clinic for their therapeutic benefit. Here, we describe the discovery of ZN-c5, an orally bioavailable SERD with favorable pharmacokinetic properties and potent activities against both wild-type and mutant ER. In vivo studies showed that ZN-c5 treatment resulted in significant tumor growth inhibition in a variety of breast cancer models and patient-derived xenograft models that harbor ESR1 mutations. Combination with CDK4/6 inhibitors or PI3K pathway inhibition enhanced anti-tumor effects compared with single agent alone. ZN-c5 also demonstrated bone protective effect as observed in a mouse osteoporosis model. These data support the clinical utility of ZN-c5 as monotherapy and as a combination therapy for patients with ER+/HER2- breast cancers. While encouraging plasma exposure and tolerability have been observed for ZN-c5 in patients, further studies are needed to optimize its therapeutic efficacy.

Duke Scholars

Published In

Mol Cancer Ther

DOI

EISSN

1538-8514

Publication Date

December 12, 2025

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3101 Biochemistry and cell biology
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ma, J., Hegde, S., Sergeeva, M., Chakraborty, B., Wardell, S. E., McDonnell, D. P., … Samatar, A. A. (2025). The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Anti-Tumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. Mol Cancer Ther. https://doi.org/10.1158/1535-7163.MCT-25-0315
Ma, Jianhui, Sayee Hegde, Masha Sergeeva, Binita Chakraborty, Suzanne E. Wardell, Donald P. McDonnell, Peter Q. Huang, et al. “The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Anti-Tumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models.Mol Cancer Ther, December 12, 2025. https://doi.org/10.1158/1535-7163.MCT-25-0315.
Ma J, Hegde S, Sergeeva M, Chakraborty B, Wardell SE, McDonnell DP, et al. The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Anti-Tumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. Mol Cancer Ther. 2025 Dec 12;
Ma, Jianhui, et al. “The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Anti-Tumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models.Mol Cancer Ther, Dec. 2025. Pubmed, doi:10.1158/1535-7163.MCT-25-0315.
Ma J, Hegde S, Sergeeva M, Chakraborty B, Wardell SE, McDonnell DP, Huang PQ, Bunker KD, Doñate F, Lackner MR, Samatar AA. The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Anti-Tumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. Mol Cancer Ther. 2025 Dec 12;

Published In

Mol Cancer Ther

DOI

EISSN

1538-8514

Publication Date

December 12, 2025

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3101 Biochemistry and cell biology
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 1112 Oncology and Carcinogenesis